Clinical Research Directory

Inclusion Criteria: * Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related * age of ≥25 years old * Performance Score ≥70 in accordance with the Karnofsky Performance Score (KPS), * life expectancy period of at least 3 months on the screening day, * Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) * subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception * adequate blood, liver, renal and urine parameters * phosphate levels within normal range * HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus), * adequate cardiac function Inclusion Criteria Specific for parts: Part 1 * Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options. Part 2 and 3 * Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options. * Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy. * Present molecular alteration within FGFR 1, 2 or 3 Exclusion Criteria: * Any other current malignancy or malignancy diagnosed within the past five (5) years. * Active brain metastases or leptomeningeal metastases. * concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment, * prior therapy with an agent directed to another FGFR inhibitor, * pregnancy and/or breastfeeding, * phosphate levels above the upper limit of normal, * ectopic calcification/mineralization, * endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy, * concomitant therapies increasing calcium/phosphate serum levels, * inability to take oral medicines, * corneal disorder and/or keratopathy, * persisting toxicity related to prior therapy Grade \> 1 CTCAE v5.0, except polyneuropathy and alopecia, * clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment. * Receipt of any organ transplantation including allogeneic stem-cell transplantation. Exclusion Criteria Specific for parts: Part 2 and 3 * No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.